The Commercial Ecosystem of Biotechnology in China

Since China’s first commercial cloning company was established in September 2014 in the eastern Shandong Province with the birth of three pure-blooded Tibetan mastiff puppies (prior to this, cloning in China had been limited to scientific research), more and more companies have shown interest in investing in the technology for commercial use, especially animal husbandry. China has made rapid and tremendous progress in fields like genome sequencing and cloning field.

At the end of 2015, Chinese scientists signed a deal to establish a commercial animal cloning center in the Tianjin Economic and Technological Development Area (TEDA), edging the controversial science closer to mainstream acceptance.

China has great hopes in biotechnology industry, but also doubts to the same degree. Some participants are worried that biotechnology will become the next one after the Internet bubble since it probably will be another popular investment spot right after the Internet. However, biotechnology industry was born with doubts and cautions which is different from the advent of the Internet. Hence, it leads us to believe that the focus on biotechnology is unlikely to result in “irrational prosperity”. Meanwhile, the emerging biotechnology is demonstrating a diverse commercial ecosystem from the Internet industry.


In my opinion, biotechnology is of great importance for developing countries to solve many urgent problems such as human healthcarefood supplyagriculture and environmental protection. China, as an emerging market, lacks of commercial experience as well as original innovations, and the suitable and effective ways to transform the science and technology achievements into products. However, given the momentum underway, the sheer scale of the effort expended and its immense market size, China will ultimately create a healthy and prosperous commercial ecosystem for the development of biotechnology industry.

Rani Jarkas, the Chairman of Cedrus Investments.

Rani Jarkas is a highly experienced financial services executive, with over 20 years of international banking experience. Currently, Mr. Jarkas is the Chairman of Cedrus Investments, a global boutique investment firm. Cedrus’ domain expertise is in life sciences, natural resources, energy, cleantech and nanotechnology. – Rani Jarkas